XM does not provide services to residents of the United States of America.

Daily Market Comment – Vaccine rally eases but optimism prevails



  • Vaccine hopes keep risk assets supported even as more US states clamp down
  • Dow closes in on 30,000 as growth-to-value rotation accelerates
  • Dollar steadier, euro shrugs off EU budget crisis, pound holds out for Brexit deal
  • Oil moderates ahead of OPEC+ meeting as bleak short-term outlook curbs advances

Moderna adds to vaccine euphoria

The fight against the pandemic took another major step forward on Monday after Moderna became the latest pharmaceutical company to announce a vaccine for COVID-19. Moderna’s vaccine, which has an even higher efficacy rate than Pfizer/BioNTech’s, further bolstered expectations that an end to the ravaging pandemic is nigh.

Shares on Wall Street surged on the back of the vaccine optimism, pushing the S&P 500 and Dow Jones Industrial Average into record territory. With other vaccine developers expected to announce their results in the coming weeks, a post-pandemic reality has now started to materialize and this is driving a rotation away from growth sectors such as tech and into value shares, which are predominantly ‘old economy' stocks.

That explains why the Dow Jones has been outperforming its Wall Street peers lately, while the Nasdaq has been lagging as stay-at-home companies that were boosted from the lockdowns are not as attractive when a full reopening looms on the horizon. Yesterday’s gains have placed the Dow just 50 points away from the psychologically important 30,000 mark – a remarkable achievement given the unprecedented crisis the world is facing right now.

The growth-to-value rotation is even more evident in Europe where traditional stocks have been enjoying a strong revival since Pfizer’s vaccine breakthrough, with London’s FTSE 100 and the Paris CAC 40 shining bright.

European shares opened marginally lower on Tuesday and US stock futures were also pointing to a small pullback.

Mainly risk-on, but some caution

The risk-on mood reverberated through the currency markets as well, boosting the commodity dollars as growth-sensitive commodities like oil and copper soared. The aussie, kiwi and loonie were slightly softer today after reclaiming key levels.

It was a somewhat more cautious tale in bond markets as government bond yields failed to jump to anywhere near last week’s highs, potentially signalling increasing pessimism about the near-term situation. New infections continue to escalate in Europe and the United States, raising doubts about whether or not virus restrictions will be substantially lifted in time for Christmas.

In America, more and more states are imposing tougher curbs to try and contain the virus and in the absence of fresh fiscal stimulus, the Fed is worried. Fed chief Jerome Powell is due to speak later today (18:00 GMT) and may comment on the economy, though his deputy, Richard Clarida, sounded relatively more upbeat in remarks yesterday than his colleagues have done recently.

Dollar pressured, euro and pound stay chirpy

Still, growing expectations that the Fed will have to beef up its asset purchases soon may be what’s curtailing Treasury yields from shooting higher on the vaccine headlines and could also be weighing on dollar/yen.

The pair has slumped to a one-week low, pulling the dollar index down too. The euro continued to edge higher despite Hungary and Poland yesterday vetoing the European Union’s next seven-year budget as well as the virus relief package over a dispute about how funds will be distributed. The market reaction suggests investors expect the spat to be resolved at the upcoming EU summit, while traders are also upbeat about the prospect of a Brexit deal.

The pound was up 0.3% following a report in ‘The Sun’ newspaper that the UK’s chief negotiator, David Frost, has told Boris Johnson to expect a deal on a post-Brexit trade accord to be reached “early next week”.

Oil eyes OPEC+ meeting as virus flare-up bites into demand

Oil prices crept higher on Tuesday, but the latest bout of vaccine euphoria could only offer a mild boost in comparison to last week’s rally. This could be an indication that the vaccine story is mostly priced in now and further gains have become preconditioned on the demand picture for the winter months improving substantially.

Investors are also waiting to see what OPEC and its allies will decide about output cuts in a meeting today. The OPEC+ alliance of major producers is expected to delay the planned easing of supply restrictions due to take effect in January by at least three months.

WTI and Brent crude were last trading up by about 0.5%.

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.